Home / World Marketplace / Archive by category Global Health & Biotech

Archive by category Global Health & Biotech

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (Korea Bizwire) – TrialWire®, the industry’s fastest, intelligent patient recruitment engine breaking the bottleneck in clinical development, proudly supported Endpoints News’ 2025 Clinical Trials Day in New York City. The event gathered leaders from across the biopharma ecosystem to discuss the evolution of clinical research and how technology continues to improve patient access and [...]

Teva Releases Q4 2025 Aide Memoire

TEL AVIV, Israel, Dec. 12, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist [...]

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH SAN DIEGO, Dec. 11, 2025 (Korea Bizwire) – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, [...]

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synerg

SPRING, Texas, Dec. 11, 2025 (Korea Bizwire) – Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today presentation at the San Antonio Breast Cancer Symposium, in San Antonio, TX; of data from preclinical studies demonstrating effectiveness of IRX4204, the company’s phase II clinical stage retinoid X nuclear receptor (RXR) agonist [...]

Impulse Dynamics Completes $158M Financing Round

Investment to Fuel Strategic Growth and Future Product Commercialization Marlton, NJ, Dec. 10, 2025 (Korea Bizwire) – Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced today that it raised more than $158 million in financing to enhance commercialization and fuel both the clinical and [...]

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years. PPF is a rare lung condition, more life-threatening than many forms of cancer, causing a continuous decline in lung function.1,2,3 PPF is the second approved indication in China for nerandomilast, following recent approvals in [...]

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-’749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1 Teva is committed to advancing this [...]

Ascom appoints David Hale as new CEO

Ad hoc announcement pursuant to Art. 53 LR Baar, Switzerland, December 9, 2025 David Hale, an executive leader with a proven track record and over two decades of technology and industrial expertise, has been appointed by the Board of Directors of Ascom Holding AG as the new CEO of the Ascom Group. David Hale will join [...]

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, [...]